Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Giralt

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
Journal of Clinical Apheresis|December 18, 2001
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresisM Körbling, S Giralt, I Khouri, et al.
Bone Marrow Transplantation|January 1, 1993
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantationC Ippoliti, D Przepiorka, S Giralt, et al.
Blood|June 1, 1995
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cellsM Talpaz, H Kantarjian, J Liang, et al.
Leukemia & Lymphoma|May 1, 1995
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphomaD Przepiorka, R Nath, C Ippoliti, et al.
Progress in Clinical and Biological Research|January 1, 1992
Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemiaR Champlin, S Giralt, D Przepiorka, et al.
Bone Marrow Transplantation|March 9, 2011
Prognostic value of response after upfront therapy for acute GVHDR M Saliba, D R Couriel, S Giralt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 5, 2002
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantationA Shimoni, J A Gajewski, M Donato, et al.
Bone Marrow Transplantation|July 1, 1994
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemiaH M Kantarjian, M Talpaz, B Andersson, et al.
Bone Marrow Transplantation|October 16, 2002
Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentationD R Couriel, G Z Beguelin, S Giralt, et al.
Bone Marrow Transplantation|April 1, 1995
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicityK van Besien, J Tabocoff, M Rodriguez, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Journal of Clinical Apheresis|December 18, 2001
Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresisM Körbling, S Giralt, I Khouri, et al.
Bone Marrow Transplantation|January 1, 1993
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantationC Ippoliti, D Przepiorka, S Giralt, et al.
Blood|June 1, 1995
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cellsM Talpaz, H Kantarjian, J Liang, et al.
Leukemia & Lymphoma|May 1, 1995
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphomaD Przepiorka, R Nath, C Ippoliti, et al.
Progress in Clinical and Biological Research|January 1, 1992
Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemiaR Champlin, S Giralt, D Przepiorka, et al.
Bone Marrow Transplantation|March 9, 2011
Prognostic value of response after upfront therapy for acute GVHDR M Saliba, D R Couriel, S Giralt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 5, 2002
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantationA Shimoni, J A Gajewski, M Donato, et al.
Bone Marrow Transplantation|July 1, 1994
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemiaH M Kantarjian, M Talpaz, B Andersson, et al.
Bone Marrow Transplantation|October 16, 2002
Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentationD R Couriel, G Z Beguelin, S Giralt, et al.
Bone Marrow Transplantation|April 1, 1995
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicityK van Besien, J Tabocoff, M Rodriguez, et al.
Pageof 18